Danaher Corporation vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Danaher Corporation trades at $206.12 (market cap $145.83B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.14. The key difference: Danaher Corporation pays a 0.77% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and Danaher Corporation is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| DHR | KOLD | |
|---|---|---|
Market Cap | $145.83B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $242.05 | $49.39 |
52-Week Low | $161.91 | $13.58 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
No Aura AI signal available yet.
Trailing returns across standard periods
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →